Conexeu Sciences completes 12-month preclinical study of CXU tissue-restoration platform
Conexeu Sciences announced on July 7, 2026, completion of its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) 12-month preclinical study of the CXU™ platform. The study demonstrated tissue restoration in small-volume facial and large-volume (200cc-equivalent) models, and met performance benchmarks for injectability and volumizing performance required of aesthetic injectables. The company plans a predicate-based 510(k) submission for wound care in Q1 2027, targeting a 90-day FDA review, with wound care intended as the initial commercial indication and foundation for expansion into medical aesthetics.
Key facts
- 12-month preclinical study met objectives for tissue restoration in cheek (small-volume facial) model
- Study met objectives for tissue restoration in 200cc-equivalent large-volume model
- CXU™ met predefined performance benchmarks for injectability and volumizing performance
- Patent estate spans more than 40 jurisdictions including U.S., EU, Japan, and Australia, with protection pending in Canada
- Predicate-based 510(k) submission for wound care planned for Q1 2027
- GLP-1 weight-loss drug market reached roughly $79 billion in 2025, projected to approximately $190 billion by 2035
- Tissue-restoration market gap expected to nearly triple from approximately $0.7 billion to $2.0 billion by 2030
Why it matters
Conexeu has cleared a preclinical milestone supporting its stated path to FDA submission and eventual entry into the medical aesthetics market, which the company identifies as its primary commercial opportunity following initial wound care clearance.
Share
Derived from 8-K filed 2026-07-07. Not investment advice. View the source filing on SEC.gov →